Achromobacter species in cystic fibrosis: Cross-infection caused by indirect patient-to-patient contact

Journal of Cystic Fibrosis

Volumn 12, Issue 6, 2013, Pages 609-615

  Hansen, C R ^a   Pressler, T ^a   Ridderberg, W ^b   Johansen, H K ^a   Skov, M ^a  

^a University of Copenhagen   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Achromobacter xylosoxidans; Cross infection; Pulmonary infection

Indexed keywords

BRONCHODILATING AGENT; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; DORNASE ALFA; IMIPENEM; PANCREAS ENZYME; PIPERACILLIN; TAZOBACTAM; TIGECYCLINE;

ACHROMOBACTER; ACHROMOBACTER RUHLANDII; ACHROMOBACTER XYLOSOXIDANS; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ASTHMA; BACTERIAL COLONIZATION; BACTERIAL TRANSMISSION; BLOOD SAMPLING; CASE REPORT; CHILD; CROSS INFECTION; CYSTIC FIBROSIS; DETERIORATION; ENDOSCOPIC SINUS SURGERY; ENZYME REPLACEMENT; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HAEMOPHILUS INFLUENZAE; HUMAN; INFANT; INFECTION; LUNG INFECTION; LUNG LAVAGE; MALE; MECONIUM ILEUS; MORAXELLA CATARRHALIS; MULTILOCUS SEQUENCE TYPING; NONHUMAN; PHYSIOTHERAPY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; PULSED FIELD GEL ELECTROPHORESIS; SCHOOL CHILD; SKIING; SPUTUM; SPUTUM CULTURE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY; WEIGHT REDUCTION;

ACHROMOBACTER XYLOSOXIDANS; CROSS-INFECTION; PULMONARY INFECTION;

ACHROMOBACTER; ADOLESCENT; BACTERIAL TYPING TECHNIQUES; CYSTIC FIBROSIS; ELECTROPHORESIS, GEL, PULSED-FIELD; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MULTILOCUS SEQUENCE TYPING; PARANASAL SINUSES; SPUTUM;

EID: 84888073136     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2013.05.004     Document Type: Article

References (43)

1. Hansen C.R., Pressler T., Johansen H.K., Skov M. Achromobacter xylosoxidans in cystic fibrosis: indirect patient-to-patient contact can lead to cross-infection. J Cyst Fibros 2012, 11(Supplement 1):S147. [Ref Type: Abstract].
2. Romano L., Bellodi S., Lugani F., Manno G. To the editor: alcaligenes as a pathogen in airways chronic infection in cystic fibrosis. Pediatr Pulmonol May 2003, 35(5):412-413.
3. Rønne Hansen C., Pressler T., Høiby N., Gormsen M. Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients: a retrospective case control study. J Cyst Fibros Dec 2006, 5(4):245-251.
4. Denton M., Kerr K., Mooney L., Keer V., Rajgopal A., Brownlee K., et al. Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatr Pulmonol Oct 2002, 34(4):257-261.
5. Frederiksen B., Koch C., Høiby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol Sep 1999, 28(3):159-166.
6. Høiby N., Pedersen S.S. Estimated risk of cross-infection with Pseudomonas aeruginosa in Danish cystic fibrosis patients. Acta Paediatr Scand May 1989, 78(3):395-404.
7. Ojeniyi B., Frederiksen B., Høiby N. Pseudomonas aeruginosa cross-infection among patients with cystic fibrosis during a winter camp. Pediatr Pulmonol Mar 2000, 29(3):177-181.
8. Pedersen S.S., Koch C., Høiby N., Rosendal K. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother Apr 1986, 17(4):505-516.
9. LiPuma J.J., Marks-Austin K.A., Holsclaw D.S., Winnie G.B., Gilligan P.H., Stull T.L. Inapparent transmission of Pseudomonas (Burkholderia) cepacia among patients with cystic fibrosis. Pediatr Infect Dis J Aug 1994, 13(8):716-719.
10. Mahenthiralingam E., Baldwin A., Vandamme P. Burkholderia cepacia complex infection in patients with cystic fibrosis. J Med Microbiol Jul 2002, 51(7):533-538.
11. Muhdi K., Edenborough F.P., Gumery L., O'Hickey S., Smith E.G., Smith D.L., et al. Outcome for patients colonised with Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic and the end of an epidemic. Thorax Apr 1996, 51(4):374-377.
12. Whiteford M.L., Wilkinson J.D., McColl J.H., Conlon F.M., Michie J.R., Evans T.J., et al. Outcome of Burkholderia (Pseudomonas) cepacia colonisation in children with cystic fibrosis following a hospital outbreak. Thorax Nov 1995, 50(11):1194-1198.
13. Burns J.L. Burkholderia cepacia-a transmissible cystic fibrosis pathogen. J Pediatr Nov 2001, 139(5):618-619.
14. Döring G., Høiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros Jun 2004, 3(2):67-91.
15. France M.W., Dodd M.E., Govan J.R., Doherty C.J., Webb A.K, Jones A.M. The changing epidemiology of Burkholderia species infection at an adult cystic fibrosis centre. J Cyst Fibros Sep 2008, 7(5):368-372.
16. Saiman L., Siegel J. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect Control Hosp Epidemiol May 2003, 24(5 Suppl.):S6-S52.
17. Ridderberg W., Wang M., Norskov-Lauritsen N. Multilocus sequence analysis of isolates of Achromobacter from patients with cystic fibrosis reveals infecting species other than Achromobacter xylosoxidans. J Clin Microbiol Aug 2012, 50(8):2688-2694.
18. Peltroche-Llacsahuanga H., Haase G., Kentrup H. Persistent airway colonization with Alcaligenes xylosoxidans in two brothers with cystic fibrosis. Eur J Clin Microbiol Infect Dis Feb 1998, 17(2):132-134.
19. Kanellopoulou M., Pournaras S., Iglezos H., Skarmoutsou N., Papagrangas E., Maniatis A.N. Persistent colonization of nine cystic fibrosis patients with an Achromobacter (Alcaligenes) xylosoxidans clone. Eur J Clin Microbiol Infect Dis Apr 2004, 23(4):336-339.
20. van Daele S., Verhelst R., Claeys G., Verschraegen G., Franckx H., van Simaey L., et al. Shared genotypes of Achromobacter xylosoxidans strains isolated from patients at a cystic fibrosis rehabilitation center. J Clin Microbiol Jun 2005, 43(6):2998-3002.
21. Raso T., Bianco O., Grosso B., Zucca M., Savoia D. Achromobacter xylosoxidans respiratory tract infections in cystic fibrosis patients. APMIS Sep 2008, 116(9):837-841.
22. Pereira R.H., Carvalho-Assef A.P., Albano R.M., Folescu T.W., Jones M.C., Leao R.S., et al. Achromobacter xylosoxidans: characterization of strains in Brazilian cystic fibrosis patients. J Clin Microbiol Oct 2011, 49(10):3649-3651.
23. Ridderberg W., Bendstrup K.E., Olesen H.V., Jensen-Fangel S., et al. Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment. J Cyst Fibros Dec 2011, 10(6):466-469.
24. Wang X., Dockery D.W., Wypij D., Fay M.E., Ferris B.G. Pulmonary function between 6 and 18years of age. Pediatr Pulmonol Feb 1993, 15(2):75-88.
25. Hankinson J.L., Odencrantz J.R., Fedan K.B. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med Jan 1999, 159(1):179-187.
26. Høiby N., Flensborg E.W., Beck B., Friis B., Jacobsen S.V., Jacobsen L. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. Scand J Respir Dis Apr 1977, 58(2):65-79.
27. Ojeniyi B., Høiby N., Rosdahl V.T. Genome fingerprinting as a typing method used on polyagglutinable Pseudomonas aeruginosa isolates from cystic fibrosis patients. APMIS Jun 1991, 99(6):492-498.
28. Johansen H.K., Moskowitz S.M., Ciofu O., Pressler T., Høiby N. Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients. J Cyst Fibros Sep 2008, 7(5):391-397.
29. Magni A., Giordano A., Mancini C., Pecoraro C., Varesi P., Quattrucci S., et al. Emerging cystic fibrosis pathogens: incidence and antimicrobial resistance. New Microbiol 2007 Jan, 30(1):59-62.
30. Saiman L., Chen Y., Tabibi S., San Gabriel P., Zhou J., Liu Z., et al. Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. J Clin Microbiol Nov 2001, 39(11):3942-3945.
31. Wainwright C.E., France M.W., O'Rourke P., Anuj S., Kidd T.J., Nissen M.D., et al. Cough-generated aerosols of Pseudomonas aeruginosa and other bacteria from cystic fibrosis patients. Thorax Jul 1 2009.
32. Van Daele S.G., Franckx H., Verhelst R., Schelstraete P., Haerynck F., Van Simaey L., et al. Epidemiology of Pseudomonas aeruginosa in a cystic fibrosis rehabilitation centre. Eur Respir J Mar 2005, 25(3):474-481.
33. de Baets F., Schelstraete P., van Daele S., Haerynck F., Vaneechoutte M. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. J Cyst Fibros Jan 2007, 6(1):75-78.
34. Lambiase A., Catania M.R., Del P.M., Rossano F., Terlizzi V., Sepe A., et al. Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis Aug 2011, 30(8):973-980.
35. Tan K., Conway S.P., Brownlee K.G., Etherington C., Peckham D.G. Alcaligenes infection in cystic fibrosis. Pediatr Pulmonol Aug 2002, 34(2):101-104.
36. Dunne W.M., Maisch S. Epidemiological investigation of infections due to Alcaligenes species in children and patients with cystic fibrosis: use of repetitive-element-sequence polymerase chain reaction. Clin Infect Dis Apr 1995, 20(4):836-841.
37. Moissenet D., Baculard A., Valcin M., Marchand V., Tournier G., Garbarg-Chenon A., et al. Colonization by Alcaligenes xylosoxidans in children with cystic fibrosis: a retrospective clinical study conducted by means of molecular epidemiological investigation. Clin Infect Dis Feb 1997, 24(2):274-275.
38. Spicuzza L., Sciuto C., Vitaliti G., Di Dio G., Leonardi S., La Rosa M. Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients. Eur J Clin Microbiol Infect Dis Feb 2009, 28(2):191-195.
39. Hansen C.R., Pressler T., Nielsen K.G., Jensen P.O., et al. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J Cyst Fibros Jan 2010, 9(1):51-58.
40. Aanaes K., von Buchwald C., Hjuler T., Skov M., Alanin M., Johansen H.K. Extensive sinus surgery and follow-up can eradicate pathogenic bacterial sinusitis in patients with cystic fibrosis. J Cyst Fibros 2012, 11(Supplement 1):S53. [Ref Type: Abstract].
41. Roby B.B., McNamara J., Finkelstein M., Sidman J. Sinus surgery in cystic fibrosis patients: comparison of sinus and lower airway cultures. Int J Pediatr Otorhinolaryngol Sep 2008, 72(9):1365-1369.
42. Johansen H.K., Aanaes K., Pressler T., Nielsen K.G., Fisker J., Skov M., et al. Colonisation and infection of the paranasal sinuses in cystic fibrosis patients is accompanied by a reduced PMN response. J Cyst Fibros May 15 2012.
43. Hansen S.K., Rau M.H., Johansen H.K., Ciofu O., et al. Evolution and diversification of Pseudomonas aeruginosa in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection. ISME J Jan 2012, 6(1):31-45.